<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127720</url>
  </required_header>
  <id_info>
    <org_study_id>1322/2020</org_study_id>
    <nct_id>NCT05127720</nct_id>
  </id_info>
  <brief_title>Pacemaker-based Long-term Monitoring of Sleep Apnea</brief_title>
  <acronym>ACaSA</acronym>
  <official_title>Schrittmacher-basiertes Schlafapnoe Langzeit-Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study continuously measuring all forms of arrhythmias, sleep&#xD;
      apnea during sleeping hours and physical activity using sensors in modern implanted&#xD;
      pacemakers. These measures will be correlated with the incidence of common co-morbidities&#xD;
      such as arterial hypertension, coronary artery disease, heart failure, COPD, peripheral&#xD;
      artery disease, iron insufficiency. In a long follow up perspective major adverse&#xD;
      cardiovascular events will be recorded and new risk scores will be developed, incorporating&#xD;
      machine learning techniques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ACaSA will provide detailed information on night-time SDB and its variability, daily activity&#xD;
      levels and different forms of arrhythmias such as atrial fibrillation, premature extra beats&#xD;
      and other ECG measures. These data will be correlated with different forms of subclinical&#xD;
      coronary atherosclerosis, including calcification score (Agatston-Score: stratified to 0,&#xD;
      1-10, 11-100, 101-400, &gt;400). Coronary lesions will be graded according to the CADSRAD&#xD;
      classification (minimal &lt; 10%, mild &lt; 50%, moderate 50-70%, severe &gt; 70%). Coronary plaques&#xD;
      will be classified as T1 = calcified, T2 = mixed, T3 = mixed, primarily calcified, T4 =&#xD;
      non-calcified). &quot;High risk plaque&quot;-criteria will include: low attenuation plaque,&#xD;
      napkin-ring, spotty calcification &lt; 3mm, remodelling index.&#xD;
&#xD;
      In addition, lung function testing will add information about concomitant COPD, asthma and&#xD;
      overlap-syndromes, which will be correlated to above mentioned measures as well.&#xD;
&#xD;
      The most prevalent co-morbidity is expected to be arterial hypertension. Therefore, its&#xD;
      diagnosis based on ambulatory 24-hours measurement (ABPM) and possible end organ damages such&#xD;
      as left ventricular hypertrophy will be part of the baseline assessment as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2032</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Triple CV MACE</measure>
    <time_frame>after 3 years</time_frame>
    <description>cardiovascular death, myocardial infarction and/or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triple CV MACE</measure>
    <time_frame>after 5 years</time_frame>
    <description>cardiovascular death, myocardial infarction and/or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triple CV MACE</measure>
    <time_frame>after 10 years</time_frame>
    <description>cardiovascular death, myocardial infarction and/or stroke</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bradycardia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pacemakers are usually above the age of 65 years, and suffer from common&#xD;
        co-morbidities such as arterial hypertension, coronary artery disease, heart failure, COPD,&#xD;
        peripheral artery disease, iron insufficiency, sleep disordered breathing, obesity and/or&#xD;
        physical inactivity / de-conditioning.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  implanted Microport TEO SR/DR or BOREA SR/DR pacemaker device&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any contraindication to perform a cardiac CT examination&#xD;
&#xD;
          -  eGFR &lt; 30 ml/min/1.73 m2&#xD;
&#xD;
          -  allergy against CT contrast medium&#xD;
&#xD;
          -  hyperthyreoism&#xD;
&#xD;
          -  inability of the patient to understand the study purpose and plan&#xD;
&#xD;
          -  inability of the patient to perform baseline examinations&#xD;
&#xD;
          -  pregnancy or breast-feeding; women with childbearing potential&#xD;
&#xD;
          -  estimated life expectancy below one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Wolfgang Dichtl, MD PhD</last_name>
      <phone>004351250481388</phone>
      <email>dichtl@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Agne Adukauskaite, MSc PhD</last_name>
      <phone>004351250483447</phone>
      <email>agne.adukauskaite@tirol-kliniken.at</email>
    </contact_backup>
    <investigator>
      <last_name>Philipp Spitaler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Rubatscher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010 Jul 27;122(4):352-60. doi: 10.1161/CIRCULATIONAHA.109.901801. Epub 2010 Jul 12.</citation>
    <PMID>20625114</PMID>
  </results_reference>
  <results_reference>
    <citation>Luyster FS, Kip KE, Aiyer AN, Reis SE, Strollo PJ Jr. Relation of obstructive sleep apnea to coronary artery calcium in non-obese versus obese men and women aged 45-75 years. Am J Cardiol. 2014 Dec 1;114(11):1690-4. doi: 10.1016/j.amjcard.2014.08.040. Epub 2014 Sep 16.</citation>
    <PMID>25307200</PMID>
  </results_reference>
  <results_reference>
    <citation>Hla KM, Young T, Hagen EW, Stein JH, Finn LA, Nieto FJ, Peppard PE. Coronary heart disease incidence in sleep disordered breathing: the Wisconsin Sleep Cohort Study. Sleep. 2015 May 1;38(5):677-84. doi: 10.5665/sleep.4654.</citation>
    <PMID>25515104</PMID>
  </results_reference>
  <results_reference>
    <citation>Defaye P, de la Cruz I, Martí-Almor J, Villuendas R, Bru P, Sénéchal J, Tamisier R, Pépin JL. A pacemaker transthoracic impedance sensor with an advanced algorithm to identify severe sleep apnea: the DREAM European study. Heart Rhythm. 2014 May;11(5):842-8. doi: 10.1016/j.hrthm.2014.02.011. Epub 2014 Feb 19.</citation>
    <PMID>24561163</PMID>
  </results_reference>
  <results_reference>
    <citation>Marti-Almor J, Marques P, Jesel L, Garcia R, Di Girolamo E, Locati F, Defaye P, Venables P, Dompnier A, Barcelo A, Nägele H, Burri H. Incidence of sleep apnea and association with atrial fibrillation in an unselected pacemaker population: Results of the observational RESPIRE study. Heart Rhythm. 2020 Feb;17(2):195-202. doi: 10.1016/j.hrthm.2019.09.001. Epub 2019 Sep 4.</citation>
    <PMID>31493591</PMID>
  </results_reference>
  <results_reference>
    <citation>Moubarak G, Bouzeman A, de Geyer d'Orth T, Bouleti C, Beuzelin C, Cazeau S. Variability in obstructive sleep apnea: Analysis of pacemaker-detected respiratory disturbances. Heart Rhythm. 2017 Mar;14(3):359-364. doi: 10.1016/j.hrthm.2016.11.033. Epub 2016 Nov 23.</citation>
    <PMID>27890735</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazza A, Bendini MG, Leggio M, De Cristofaro R, Valsecchi S, Boriani G. Continuous monitoring of sleep-disordered breathing with pacemakers: Indexes for risk stratification of atrial fibrillation and risk of stroke. Clin Cardiol. 2020 Dec;43(12):1609-1615. doi: 10.1002/clc.23489. Epub 2020 Nov 12.</citation>
    <PMID>33179808</PMID>
  </results_reference>
  <results_reference>
    <citation>Linz D, Brooks AG, Elliott AD, Nalliah CJ, Hendriks JML, Middeldorp ME, Gallagher C, Mahajan R, Kalman JM, McEvoy RD, Lau DH, Sanders P. Variability of Sleep Apnea Severity and Risk of Atrial Fibrillation: The VARIOSA-AF Study. JACC Clin Electrophysiol. 2019 Jun;5(6):692-701. doi: 10.1016/j.jacep.2019.03.005. Epub 2019 May 1.</citation>
    <PMID>31221356</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazza A, Bendini MG, De Cristofaro R, Lovecchio M, Valsecchi S, Boriani G. Pacemaker-detected severe sleep apnea predicts new-onset atrial fibrillation. Europace. 2017 Dec 1;19(12):1937-1943. doi: 10.1093/europace/euw371.</citation>
    <PMID>28073884</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

